Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Eur J Cardiothorac Surg. 2022 Jul 11;62(2). doi: 10.1093/ejcts/ezac307.
Sutureless aortic valve replacement (SU-SAVR) has been associated with higher rates of permanent pacemaker (PPM) compared with conventionally implanted aortic bioprostheses. The purpose of this study was to determine the incidence, predictors and mid-term prognostic impact of PPM after Perceval (Livanova, London, UK) SU-SAVR in low-risk patients.
A total of 400 consecutive low-risk (EuroSCORE II < 4%) patients without prior pacemaker who underwent surgical aortic valve replacement with the Perceval prosthesis from 2013 to 2019 in 2 centres were included. Baseline, clinical and electrocardiographic parameters, procedural characteristics and follow-up data were collected.
PPM was required in 36 (9%) patients after SU-SAVR, with a median time between the procedure and PPM implantation of 7.5 (4.5-10.5) days. Older age and prior right bundle branch block (RBBB) were associated with an increased risk of PPM (P < 0.05 for all), but only baseline RBBB was found to be an independent predictor of new PPM requirement (odds ratio: 2.60, 95% confidence interval: 1.15-5.81; P = 0.022). At a median follow-up of 3.4 (2.3-4.5) years, there were no differences between groups in mortality (PPM: 36%, no PPM: 22%, P = 0.105) or heart failure rehospitalization (PPM: 25%, no PPM: 21%, P = 0.839).
About 1 out of 10 low-risk patients with aortic stenosis undergoing SU-SAVR with the Perceval prosthesis required PPM implantation. Prior RBBB determined an increased risk (close to 3-fold) of PPM following the procedure. PPM was not associated with a higher risk of clinical events at 3-year follow-up.
与传统植入的主动脉生物瓣相比,无缝线主动脉瓣置换术(SU-SAVR)与更高的永久性起搏器(PPM)植入率相关。本研究旨在确定在两个中心,2013 年至 2019 年间使用 Perceval(Livanova,伦敦,英国)SU-SAVR 治疗低危患者后,PPM 的发生率、预测因素和中期预后影响。
共纳入 400 例连续低危(EuroSCORE II<4%)、无既往起搏器的患者,这些患者在两个中心均接受了 Perceval 假体的外科主动脉瓣置换术。收集了基线、临床和心电图参数、手术特点和随访数据。
SU-SAVR 后有 36 例(9%)患者需要植入 PPM,起搏器植入时间中位数为 7.5(4.5-10.5)天。年龄较大和既往右束支传导阻滞(RBBB)与 PPM 风险增加相关(所有 P<0.05),但仅基线 RBBB 是新植入 PPM 的独立预测因素(比值比:2.60,95%置信区间:1.15-5.81;P=0.022)。在中位数为 3.4(2.3-4.5)年的随访中,两组死亡率(PPM:36%,无 PPM:22%,P=0.105)或心力衰竭再入院率(PPM:25%,无 PPM:21%,P=0.839)无差异。
在接受 Perceval 假体 SU-SAVR 的低危主动脉瓣狭窄患者中,约每 10 例就有 1 例需要植入 PPM。术前 RBBB 增加了术后发生 PPM 的风险(接近 3 倍)。在 3 年随访时,PPM 与临床事件的风险增加无关。